(S)-N-Boc-3-Aminobutyric Acid: Looking Closer at Our Core Intermediary

Insight into Production and Application

(S)-N-Boc-3-Aminobutyric Acid, or tert-butyl (S)-3-aminobutanoate carbamate, carries its weight in chemical manufacturing, especially where enantiomeric purity and reliable protection in synthesis matter most. This molecule, with CAS number 134636-78-9, wears its Boc group with purpose: the Boc (tert-butyloxycarbonyl) group shields the amine during sensitive transformations, sparing the reactive end and letting chemists maneuver precisely through complex procedures. Years in the lab have shown us that robustness at this early stage sets the pace for later yields and minimizes risk for downstream failures.

Working up (S)-N-Boc-3-Aminobutyric Acid doesn’t call for exotic conditions. We found that its crystalline nature means it resists caking from moisture exposure if handled with reasonable care in typical warehouse humidity levels. After each batch, spot checks by chiral HPLC reassure us—and our clients—that they are receiving material with greater than 99 percent enantiomeric excess. For many, this is the true backbone of an asymmetric synthesis route.

Specifications That Matter

The acid function pairs with the protected amine to support reliable amide coupling. Our own experience tells us that minor contamination of even 0.5 percent of the opposite enantiomer, or unprotected amine, can spoil not only a single batch but jeopardize the reproducibility of a whole process. To address this, every production run of our (S)-N-Boc-3-Aminobutyric Acid undergoes verification in both our QC and development labs, with reference standards based on NMR, IR, and mass spectrometry comparison.

We have stuck to a standard particle size (range around 40–100 mesh for main lot deliveries) for consistent handling and blending in solution or solid-phase synthesis. Chemists relying on reproducible reactivity in peptide or small molecule assembly avoid headaches related to solubility differences or slow dissolution, both of which become especially troublesome when scale-up looms.

Role in Synthesis—What We’ve Seen Over the Years

Practical applications build on its stable Boc block. For peptide synthesis, (S)-N-Boc-3-Aminobutyric Acid enables the introduction of the (S)-3-aminobutyric acid motif into growing peptide chains, where the chirality proves crucial for binding affinity in drug candidates. We have shipped this compound to pharmaceutical groups using it for β-amino acid-based peptidomimetics and also to agrochemical labs screening new bioactive molecules. The directness and reliability of the Boc group have saved research teams days of repeated protection/deprotection cycles or the need to troubleshoot product decomposition.

Research teams at several generics manufacturers often comment that cost per kilo matters less when each gram achieves consistent, clear-cut results during convergence steps. In one recent customer pilot, a batch made with our product ran without any loss in enantiomeric content after coupling and deprotection: project timelines shortened, and material saved with almost no byproduct. That sort of testimonial keeps us devoted to batch consistency and strong analytical checks.

Product Differences and Market Alternatives

(S)-N-Boc-3-Aminobutyric Acid distinguishes itself from racemates and from unprotected analogues. Racemates, sometimes considered as ‘universal’ raw materials, look cheaper on a price sheet but lose favor during chiral resolution and regulatory filings. The (S)-form lines up with real-world clinical need, given that only enantiopure compounds can be advanced for safety and efficacy filings. Laboratories forced to rework batches or invest in post-synthesis resolution wrestle with greater solvent waste and lower environmental compliance.

Some labs have set up in-house Boc-protection right from raw aminobutyric acid. Tackling this operation at scale introduces risk: incomplete conversion, unstable intermediates, or an off-color product that won’t pass regulatory review. Our production line runs large-scale Boc protection under optimized pressure, temperature, and time, generating uniform product with clear endpoints and consistent lot-to-lot color and assay results. In short, clients report a sharply reduced tendency towards stuck filtrations and messy chromatograms after switching to our supplied product.

Unpacking the Supply Side—Why Our Process Is Built This Way

Manufacturing this intermediate starts with sourcing of high-purity (S)-3-aminobutyric acid. Partnerships with reliable upstream producers mean we don’t gamble on seed crystal habits or batch irregularities. We implement a two-step reaction for Boc-protection: anhydrous solvents, precise stoichiometric Boc-anhydride addition, and controlled reaction temperature prevent over-acylation or product hydrolysis. If a change in supplier quirks yields even a faint increase in the color of crude material, our QC flags it before reaching purification.

Mother liquors captured from crystallization don’t go down the drain. Careful recovery keeps solvent-related emissions down and lets us reuse certain clean streams for subsequent cycles. One trial in our plant shaved ten percent off per-kilo solvent requirements just by deploying a feedback loop from the filter-press step into primary crystallization.

After drying, the powder stays white—no persistent yellowing or streaking. Warehouse staff often comment that strong batch identity and minimal dust formation help both in storage and weighing, keeping loading times efficient and reducing airborne losses.

Regulatory and Documentation Trail

(S)-N-Boc-3-Aminobutyric Acid is not classified as hazardous for transport. We established uniform labeling and documentation practices to meet both GMP-aligned pharma requests and R&D screening needs. Stability data supports at least two years storage under standard ambient conditions in sealed containers, so our clients don’t discover product degradation at an awkward point in their schedules.

Several regulatory filings have involved our product as a listed synthetic intermediate, and audits have reviewed our full traceability of each batch component. We maintain CoA records for all released product, matching NMR, IR, and chiral chromatogram data to each lot. EHS teams and QA reviewers receive batch-specific trace impurity profiles, requested especially by larger multinational buyers not satisfied with just an average spec sheet.

Feedback from End Users

Regular users—peptide houses, biotech scale-up teams, and custom synthesis labs—call our lot-to-lot consistency an insurance policy. Peptide bond formation reactions, liver enzyme stability assays, and pilot plant scale-ups stand or fall on the certainty that each kilo yields the expected product profile.

One client told us about their prior struggle with imported material falling short on enantiomeric excess, which led to an unwelcome spike in purification costs, wasted solvents, and missed project deadlines. Switching to our version took uncertainty off the table, paving the way for better resource use. We have seen material picked up for early preclinical work and then reused without any adverse trend in physical quality or yield, run after run.

Scale Handling and Storage Practice

Plant staff often report that (S)-N-Boc-3-Aminobutyric Acid powders pack well and present few flow issues during bag or drum emptying. For those blending it straight into solvent or solid-phase supports, low static and fine granule habit mean minimal loss or clumping in feeders. Our packs always arrive with clear lot identifiers and tamper-evident seals, helping chemists track inventory across project lines.

Measures to make sure that ambient moisture or temperature swings don’t degrade quality include multi-layer pouches and quick resealing protocols on opened inventory. In practice, this means minimal sample waste or loss of spec, even in humid summer conditions.

Research and Development—Driving Change by Listening to Problems

From the bench upwards, our R&D team favors close calls with end users to spot bottlenecks. Years back, a Japanese partner highlighted yield drops and increased side-product in their peptide extension sequence. With direct feedback, we tightened up our crystallization endpoint, sharpening the product’s melting profile and making chromatographic separation much crisper. That one tweak cut purification time and enabled a jump in overall throughput.

Peptide manufacturers sometimes probe for lower-level byproducts—unknowns below 0.1 percent. In response, our analytical division implemented liquid chromatography–mass spectrometry (LC-MS) screening as a routine for post-filtration product evaluation. Over the last year, we logged zero out-of-spec shipments, and our return authorization incident rate stayed at zero for this product.

Environmental and Sustainability Practices

Plants handling sizable Boc-deprotection streams worry about the waste profile. We support applications with full documentation on trace metal content, organics, and residual solvents, helping downstream clients meet environmental compliance without surprises.

Solvent recycling and emission abatement get priority in our operations, since manufacturing protected amino intermediates generates some volatile organic compound (VOC) load. Our process tuning over the last five years lowered our footprint by almost twenty percent. We work with regional agencies to stay above required standards—not just to pass audits but to carry out good neighbor practice.

Clients with green-chemistry targets prize our ability to adjust solvent use by batch. For specialty runs, we can divert from more common DMF to less impactful alternates or minimize volumes with higher concentration cycles, reducing both carbon load and downstream disposal charges.

Challenges and Approaches to Solutions

Steady supply of high-purity starting material can falter with commodity price swings or upstream crop failures, especially as the world shifts to more regulated, sustainable agriculture. We hedge supply risk with multi-source contracts and maintain safety stocks. Production doesn’t rest on single vendors, so temporary disruption never pushes us to cut corners or release lower-quality product.

Odor generation during Boc protection sometimes proves a nuisance at scale, particularly with venting needed for large reactors. Our team engineered a closed-loop off-gas trap for t-butyl byproduct, slashing plant odor complaints and reclaiming a useful stream for in-house reuse.

Transportation changes, from regulatory reclassification to new packaging mandates, get proactive treatment. We pilot new pack-out formats, lightening the overall package weight and trimming raw plastic use by up to fifteen percent in some container lines.

Why Enantiopurity Remains Key in Pharmaceutical Synthesis

Pharmaceutical, crop protection, and advanced material projects all place a premium on chirality. Regulatory filings for APIs call for strict controls over isomer content to secure approvals and prove patient safety. A protected amino acid like (S)-N-Boc-3-Aminobutyric Acid, supplied with chiral assurance and detailed impurity mapping, becomes more than a commodity—it serves as a plug-and-play intermediate that makes sense both scientifically and operationally.

Several years in, clients who originally insisted on making their own protection steps migrated to purchased intermediates. Time studies showed process steps dropped by as much as a full day, batch reproducibility jumped, and groups could share protocols across international sites without recalibration or rework. These case studies continue to drive us in pushing both quality and documentation further, supporting not just the immediate buyer but the product’s end user facing tight margins, regulatory scrutiny, and rapid development cycles.

Concluding Perspective

Handling (S)-N-Boc-3-Aminobutyric Acid demands technical awareness and attention to process detail, rooted in practical experience. From selection of starting chiral amines through to optimized Boc-protection and final pack-out, tight systems reduce error and shift risk off the bench chemist. Our plant continues to update its workflow to give scientists reliable, high-purity intermediates ready for complex synthetic journeys.

Strong analytical control, environmental improvement, and a habit of addressing technical feedback all keep this intermediate positioned as a favored choice in both established and emerging chemistries. Experience on the production floor, combined with ongoing dialogue with front-line synthetic teams, shapes how we keep getting better. Every outgoing batch drives a chain of research, application, and new medicines discovery—proof that even foundational intermediates like (S)-N-Boc-3-Aminobutyric Acid play a role much larger than their weight.